NovaBridge Biosciences (NBP) Enterprise Value (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Enterprise Value for 8 consecutive years, with -$207.2 million the latest figure, recorded in Q4 2025.

• Quarterly Enterprise Value fell 19.51% year-over-year to -$207.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$207.2 million (down 19.51% YoY) and the FY2025 annual result came in at -$207.2 million, down 19.51% from the prior year.
• Enterprise Value climbed to -$207.2 million in Q4 2025 per NBP's latest filing, from -$228.3 million in the prior quarter.
• Over the last five years, Enterprise Value for NBP reached as high as -$165.6 million in Q2 2025 and fell as low as -$118.4 billion in Q4 2021.
• A 5-year average of -$9.4 billion and a median of -$228.3 million in 2025 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2021 — Enterprise Value slumped 16273.69% — and 2022, when it jumped 99.59%.
• Year by year, Enterprise Value stood at -$118.4 billion in 2021, then soared by 99.59% to -$485.0 million in 2022, then surged by 34.58% to -$317.3 million in 2023, then surged by 45.35% to -$173.4 million in 2024, then fell by 19.51% to -$207.2 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$207.2 million, -$228.3 million, and -$165.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.